Vedolizumab as induction and maintenance therapy for ulcerative colitis
Brian G Feagan1, Paul Rutgeerts, Bruce E Sands
1Robarts Clinical Trials, Robarts Research Institute, and Department of Medicine, University of Western Ontario, London, Canada. bfeagan@robarts.ca
The New England Journal of Medicine
|August 23, 2013
Summary
Vedolizumab demonstrated superior efficacy compared to placebo for both initiating and sustaining treatment in ulcerative colitis patients. Adverse event rates were comparable between groups, indicating a favorable safety profile for vedolizumab therapy.
Area of Science:
- Gastroenterology
- Immunology
- Clinical Trials
Background:
- Ulcerative colitis (UC) is a chronic inflammatory bowel disease.
- Vedolizumab targets gut-selective lymphocyte trafficking, offering a potential therapeutic strategy for UC.
Purpose of the Study:
- To evaluate the efficacy and safety of vedolizumab as induction and maintenance therapy for active ulcerative colitis.
Main Methods:
- Two integrated, randomized, double-blind, placebo-controlled trials were conducted.
- Patients received vedolizumab or placebo for induction, with responders continuing vedolizumab or switching to placebo for maintenance up to 52 weeks.
Main Results:
- Vedolizumab showed significantly higher response rates at week 6 compared to placebo (47.1% vs. 25.5%).
- Clinical remission rates at week 52 were substantially higher for patients on vedolizumab (every 8 or 4 weeks) versus placebo (44.8% vs. 15.9%).
- Adverse event frequencies were similar across vedolizumab and placebo groups.
Conclusions:
- Vedolizumab is an effective induction and maintenance therapy for ulcerative colitis.
- The safety profile of vedolizumab is comparable to placebo in UC patients.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...